HK1007680A1 - Pharmacological treatment of ocular development - Google Patents

Pharmacological treatment of ocular development

Info

Publication number
HK1007680A1
HK1007680A1 HK98106919A HK98106919A HK1007680A1 HK 1007680 A1 HK1007680 A1 HK 1007680A1 HK 98106919 A HK98106919 A HK 98106919A HK 98106919 A HK98106919 A HK 98106919A HK 1007680 A1 HK1007680 A1 HK 1007680A1
Authority
HK
Hong Kong
Prior art keywords
pharmacological treatment
ocular development
ocular
development
eye
Prior art date
Application number
HK98106919A
Other languages
English (en)
Inventor
Richard A Stone
Alan M Laties
Paul M Iuvone
Original Assignee
Univ Pennsylvania
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Univ Emory filed Critical Univ Pennsylvania
Publication of HK1007680A1 publication Critical patent/HK1007680A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK98106919A 1988-06-03 1998-06-26 Pharmacological treatment of ocular development HK1007680A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20222088A 1988-06-03 1988-06-03
US34294289A 1989-04-25 1989-04-25
PCT/US1989/002407 WO1989011854A1 (en) 1988-06-03 1989-06-01 Pharmacological treatment of ocular development

Publications (1)

Publication Number Publication Date
HK1007680A1 true HK1007680A1 (en) 1999-04-23

Family

ID=26897480

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98106919A HK1007680A1 (en) 1988-06-03 1998-06-26 Pharmacological treatment of ocular development

Country Status (8)

Country Link
US (2) US5284843A (xx)
EP (1) EP0422068B1 (xx)
JP (1) JP2741624B2 (xx)
AT (1) ATE110957T1 (xx)
CA (1) CA1336490C (xx)
DE (1) DE68918099T2 (xx)
HK (1) HK1007680A1 (xx)
WO (1) WO1989011854A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
DE69033246T2 (de) * 1989-06-21 1999-12-02 Univ Pennsylvania Behandlung und Regulierung der Augenentwicklung mit cholinergischen Agonisten
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
US5744468A (en) * 1996-10-23 1998-04-28 Tong-Ho Lin Hypotensive intraocular pressure activity of clozapine and sulpiride
US20030096831A1 (en) * 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
AU2001264564A1 (en) * 2000-05-02 2001-11-12 Central Institute For The Deaf Composition and methods for treating photoreceptor degeneration
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
FI20075498A (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
MX370302B (es) * 2013-09-30 2019-12-09 Orion Corp Composición de ropinirol para usarse en la inducción de emesis en los animales.
US10823982B2 (en) 2014-06-03 2020-11-03 Tsubota Laboratory, Inc. Myopia treatment device
WO2015186723A1 (ja) * 2014-06-03 2015-12-10 株式会社 坪田ラボ 近視予防物品
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
JP6508536B2 (ja) * 2016-05-19 2019-05-08 株式会社小出光学 眼球模型群セット
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
DE69033246T2 (de) * 1989-06-21 1999-12-02 Univ Pennsylvania Behandlung und Regulierung der Augenentwicklung mit cholinergischen Agonisten
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
US5571823A (en) 1996-11-05
CA1336490C (en) 1995-08-01
DE68918099T2 (de) 1995-01-05
JPH06502839A (ja) 1994-03-31
EP0422068B1 (en) 1994-09-07
EP0422068A4 (en) 1992-01-08
DE68918099D1 (de) 1994-10-13
WO1989011854A1 (en) 1989-12-14
US5284843A (en) 1994-02-08
ATE110957T1 (de) 1994-09-15
JP2741624B2 (ja) 1998-04-22
EP0422068A1 (en) 1991-04-17

Similar Documents

Publication Publication Date Title
EP0422068A4 (en) Pharmacological treatment of ocular development
CA2030459A1 (en) Biodegradable ocular implants
TW249226B (xx)
EP0199768A4 (en) METHOD FOR PREVENTING EYE HYPERTENSION, TREATING GLAUCOMA AND TREATING EYE HYPERTENSION.
EG18268A (en) Medicament for the treatment of inflammation of the eye
EP0506840A4 (en) Method of treating ocular diseases by periocular administration of cyclosporine a or g
FI920601A0 (fi) Tvaofasig anordning foer transdermal dosering av laekemedel.
EP0407008A3 (en) Fibronectin fragment
AU3693789A (en) New ophthalmic preparation for treating glaucoma
AU3327489A (en) Ophthalmic solution for intraocular pressure adjustment
GR1002329B (el) Μεθοδος για την παραγωγη αλατων κλαβουλανικου οξεος.
ES8401317A1 (es) Mejoras introducidas en la manufactura de un inserto ocular biosoluble.
EP0478694A4 (en) Treatment and control of ocular development
AU2706788A (en) Method of inhibiting virus
AU3817789A (en) Bandage for maintaining anterior chamber of eye
ATE181829T1 (de) Gaba-erge modulation des augenwachstums
EP0430551A3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2200481A1 (en) Method and means for prevention and treatment of secondary cataract
EP0140789A3 (en) Ophthalmic composition containing a peripherally selective dopamine antagonist, for the treatment of ocular hypertension
GB2210993B (en) An ocular attachment for an endoscope
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
IE872087L (en) Treating contact lenses
AU6808290A (en) Method for the treatment of glaucoma
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses
AU6149690A (en) Tetrahydrobenzothiazole derivatives for treating diseases of the eye

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060601